Single-dose azithromycin for Chlamydia in pregnant women

Clicks: 450
ID: 112904
1998
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Azithromycin in the treatment of C trachomatis in pregnant women substantially improved the cure rates while substantially reducing the occurrence of severe side effects associated with the use of a standard course of erythromycin. Since both tetracycline and erythromycin are known to be effective a …
Reference Key
ha1998thesingle-dose Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Wehbeh HA;Ruggeirio RM;Shahem S;Lopez G;Ali Y;;
Journal the journal of reproductive medicine
Year 1998
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/9653697
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine pregnancy logistic models research support non-u.s. gov't female Clinical Trial Randomized Controlled Trial pregnancy complications sexual partners anti-bacterial agents / therapeutic use* gestational age chlamydia infections / drug therapy* pmid:9653697 h a wehbeh r m ruggeirio y ali azithromycin / administration & dosage azithromycin / therapeutic use* erythromycin / administration & dosage erythromycin / therapeutic use infectious / drug therapy* tetracycline / administration & dosage tetracycline / therapeutic use

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.